Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients

Psychopharmacology

Volumn 175, Issue 3, 2004, Pages 367-373

  Bressan, Rodrigo A ^a,b   Erlandsson, Kjell ^c   Spencer, Edgar P ^d   Ell, Peter J ^c   Pilowsky, Lyn S ^a,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Amisulpride; Antipsychotic agents; Atypical antipsychotic; D2 dopamine; Dopamine receptor; Neuroleptic; Photon emission tomography; Prolactin; Schizophrenia; SPECT; 123I epidepride

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; EPIDEPRIDE; IODINE 123; NEUROLEPTIC AGENT;

ADULT; AKATHISIA; ARTICLE; BLOOD BRAIN BARRIER; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG BLOOD LEVEL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TARDIVE DYSKINESIA; TEMPORAL CORTEX; THALAMUS;

EID: 5444267926     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-1826-6     Document Type: Article

References (39)

1. Addington D, Addington J, Maticka-Tyndale E, Joyce J (1992) Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 6:201-208
2. Alcohol Drug Abuse, and Mental Health Administration (1974) Abnormal involuntary movement scale (AIMS). Department of Health, Education and Welfare, Washington D.C.
3. Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676
4. 123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 160:1413-1420
5. 123I]-epidepride SPET study. J Clin Psychopharmacol 23:5-14
6. Brown WA, Laughren TP (1981) Tolerance to the prolactin-elevating effect of neuroleptics. Psychiatry Res 5:317-322
7. 123I]epidepride: resolving conflicting findings. Neuroimage 19:1205-1214
8. Flores CM, Hulihan-Giblin BA, Hornby PJ, Lumpkin MD, Kellar KJ (1992) Partial characterization of a neurotransmitter pathway regulating the in vivo release of prolactin. Neuroendocrinology 55:519-528
9. Folstein M, Folstein F, McHugh P (1975) Mini mental state - a practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res 12:189-198
10. Gruen PH, Sachar EJ, Langer G, Altman N, Leifer M, Frantz A, Halpern FS (1978) Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch Gen Psychiatry 35:108-116
11. Grunder G, Wetzel H, Schlosser R, Anghelescu I, Hillert A, Lange K, Hiemke C, Benkert O (1999) Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiatry 45:89-97
12. Igarashi Y, Higuchi T, Toyoshima R, Noguchi T, Moroji T (1985) Tolerance to prolactin secretion in the long-term treatment with neuroleptics in schizophrenia. Adv Biochem Psychopharmacol 40:95-98
13. Invitti C, Danesi L, Dubini A, Cavagnini F (1998) Neuroendocrine effects of chronic administration of sodium valproate in epileptic patients. Acta Endocrinol 118:381-388
14. Jaber M, Robinson SW, Missale C, Caron MG (1996) Dopamine receptors and brain function. Neuropharmacology 35:1503-1519
15. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520
16. Kapur S, Langlois X, Vinken P, Megens AA, de Coster R, Andrews JS (2002) The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 302:1129-1134
17. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276
18. Kuruvilla A, Peedicayil J, Srikrishna G, Kuruvilla K, Kanagasabapathy AS (1992) A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol 19:603-606
19. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153-158
20. 11C] raclopride studies. J Cereb Blood Flow Metab 16:42-52
21. Laughren TP, Brown WA, Williams BW (1979) Serum prolactin and clinical state during neuroleptic treatment and withdrawal. Am J Psychiatry 136:108-110
22. Leucht S, Pitschel-Walz G, Engel RR, Kissling W (2002) Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 159:180-190
23. 2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology 124:154-158
24. Melkersson KI, Hulting AL, Rane AJ (2001) Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol 51:317-324
25. Meltzer HY (1985) Long-term effects of neuroleptic drugs on the neuroendocrine system. Adv Biochem Psychopharmacol 40:59-68
26. Meltzer HY, Fang VS (1976) The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 33:279-286
27. Mizuchi A, Kitagawa N, Miyachi Y (1983) Regional distribution of sultopride and sulpiride in rat brain measured by radioimmunoassay. Psychopharmacology 81:195-198
28. Monteleone P, Maj M, Ariano MG, Iovino M, Fiorenza L, Steardo L (1998) Prolactin response to sodium valproate in schizophrenics with and without tardive dyskinesia. Psychopharmacology 96:223-226
29. Naber D, Fischer H, Ackenheil M (1979) Effect of long-term neuroleptic treatment on dopamine tuberoinfundibular system: development of tolerance? Commun Psychopharmacol 3:59-65
30. 2 receptor occupancy in antipsychotic drug-treated patients. J Clin Psychopharmacol 18:305-310
31. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227-235
32. Overall J, Gorham D (1962) The brief psychiatric rating scale. Psychol Rep 10:799-812
33. Protais P, Hermier C, Costentin J (1985) The discriminant dopamine antagonist property of benzamides is observed at various times after their systemic or intracerebroventricular administration. Neuropharmacology 24:861-867
34. Rao ML, Brown WA (1987) Stability of serum neuroleptic and prolactin concentrations during short-term and long-term treatment of schizophrenic patients. Psychopharmacology 93:237-242
35. Rivera JL, Lal S, Ettigi P, Hontela S, Muller HF, Friesen HG (1976) Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol (Oxf) 5:273-282
36. Schlosser R, Grunder G, Anghelescu I, Hillert A, Ewald-Grunder S, Hiemke C et al. (2002) Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology 46:33-40
37. Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11-19
38. Talairach J, Tourneaux P (1988) Co-planar stereotactic atlas of the human brain. Thieme, New York
39. 2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol 21:207-214